Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q9UFF9
UPID:
CNOT8_HUMAN
Alternative names:
CAF1-like protein; CAF2; CCR4-associated factor 8; Caf1b
Alternative UPACC:
Q9UFF9; B0AZS3; B2RAR8; B7Z8R1; D3DQI8; O95709; Q7Z521; Q9H6Y1
Background:
CCR4-NOT transcription complex subunit 8, known as CAF1-like protein, CAF2, CCR4-associated factor 8, or Caf1b, plays a crucial role in mRNA degradation, miRNA-mediated repression, and translational repression during initiation. It exhibits 3'-5' poly(A) exoribonuclease activity and works in tandem with CNOT7. As a part of the CCR4-NOT complex, it influences various cellular processes and mRNA expression, associating with BTG family members like TOB1 and BTG2 to exert anti-proliferative effects.
Therapeutic significance:
Understanding the role of CCR4-NOT transcription complex subunit 8 could open doors to potential therapeutic strategies.